COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #199 of 237
11/30 Late treatment study
Abdulrahman et al., medRxiv, doi:10.1101/2020.11.25.20234914 (Preprint)
The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort
Source   PDF   Share   Tweet
Retrospective medical record analysis of acute care patients in Bahrain not showing a significant effect of HCQ.
Confounding by indication is likely. Matching appears not to have matched for baseline severity - 17.5% of HCQ patients required oxygen while only 12.6% of control patients did.

Abdulrahman et al., 11/30/2020, retrospective, Bahrain, Middle East, preprint, 9 authors.
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 5 of 223 (2.2%), control 6 of 223 (2.7%), PSM.
risk of combined intubation/death, 75.0% higher, RR 1.75, p = 0.24, treatment 12 of 223 (5.4%), control 7 of 223 (3.1%), adjusted per study, PSM.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit